Patients with chronic kidney disease have 4 to 8 times higher risk of bone fractures than people with healthy kidneys, according to Gram Research analysis of current evidence. This happens because damaged kidneys can’t properly control minerals and vitamin D activation, which weakens bone structure. The good news: several proven treatments exist to reduce fracture risk, but most high-risk patients aren’t receiving them due to outdated beliefs that nothing can help.
People with chronic kidney disease face a serious but often overlooked problem: their bones become weak and break much more easily than healthy people’s bones. According to Gram Research analysis, patients on dialysis have up to 8 times higher fracture risk than people without kidney disease. This happens because damaged kidneys can’t properly control minerals like phosphate and calcium, and can’t activate vitamin D the way they should. Researchers now understand this isn’t just about weak bones—it also affects the heart and blood vessels. The good news is that doctors have treatments available, but many high-risk patients aren’t receiving them yet. This review examines why bone health matters so much for kidney patients and what needs to change in how doctors care for them.
Key Statistics
A comprehensive review in Kidney International Reports found that patients on dialysis face up to 8 times higher fracture risk compared to age-matched controls without kidney disease, yet most high-risk patients don’t receive available bone-protective treatments.
According to research reviewed by Gram, patients with chronic kidney disease have fracture rates exceeding those of healthy people by more than 4-fold, with the risk increasing dramatically in dialysis populations due to multiple mineral and metabolic disruptions.
A 2026 review identified that kidney disease causes bone weakness through interconnected mechanisms including phosphate retention, impaired vitamin D activation, secondary hyperparathyroidism, and accumulation of uremic toxins like indoxyl sulfate and uric acid.
Research shows that kidney transplant patients face continued bone health challenges because immunosuppressive medications, glucocorticoids, and anticoagulant treatments further weaken bones despite receiving a functioning kidney.
The Quick Take
- What they studied: How chronic kidney disease damages bones and increases fracture risk, and what doctors can do about it
- Who participated: This is a review article that analyzed existing research on kidney disease patients, including those on dialysis and those who received kidney transplants
- Key finding: Patients on dialysis have 4 to 8 times higher risk of bone fractures compared to people with healthy kidneys, yet most high-risk patients don’t receive available treatments
- What it means for you: If you have kidney disease, protecting your bones should be a priority conversation with your doctor. Several proven treatments exist, but they’re underused. Ask your doctor about bone health screening and whether treatment is right for you.
The Research Details
This is a comprehensive review article published in Kidney International Reports that examines current scientific understanding of how kidney disease affects bones. Rather than conducting a new experiment, the authors analyzed existing research and clinical knowledge to identify patterns, gaps, and opportunities for improvement.
The review focuses on two main problems that develop when kidneys fail: bone weakness (similar to osteoporosis) and calcium deposits in blood vessels and the heart. The authors explain how these problems develop step-by-step, starting with the kidney’s inability to control minerals and activate vitamin D properly.
The review also evaluates the tools doctors currently use to identify at-risk patients and the treatments available to help them. The authors highlight a critical gap: many patients who need bone-protective treatment aren’t receiving it, even though safety data supports using these medications.
Review articles like this are important because they synthesize large amounts of research into a clear picture of what we know and what we don’t know. This particular review matters because bone disease in kidney patients is common but often overlooked. By identifying gaps in current practice and treatment, the authors provide a roadmap for improving patient care. The review emphasizes that therapeutic nihilism—the belief that nothing can be done—is preventing patients from receiving helpful treatments.
This is a narrative review article, which means it represents expert analysis rather than a systematic analysis of all available studies. The authors are recognized experts in kidney disease and bone health, publishing in a reputable peer-reviewed journal. However, readers should understand that review articles synthesize existing knowledge rather than provide new experimental data. The strength of this article lies in identifying clinical gaps and proposing solutions based on accumulated evidence.
What the Results Show
The research reveals that kidney disease causes bone problems through multiple interconnected mechanisms. When kidneys fail, they can’t properly regulate phosphate (a mineral), activate vitamin D, or control parathyroid hormone (a chemical that manages bone health). These problems accumulate and create a cascade of damage to bone cells.
The numbers are striking: patients with chronic kidney disease have fracture rates more than 4 times higher than people with healthy kidneys. For patients on dialysis—the most severe cases—fracture risk jumps to 8 times higher. This means a dialysis patient is far more likely to break a bone from a minor fall or injury that wouldn’t hurt a healthy person.
Interestingly, kidney disease causes a different type of bone weakness than regular osteoporosis. In kidney disease, bones can actually appear dense on standard X-ray tests, yet still break easily. This happens because the bone structure becomes disorganized and weak, even though it looks solid on imaging.
The problem intensifies after kidney transplantation because anti-rejection medications (including steroids) further weaken bones. Patients also accumulate uremic toxins—harmful substances that build up when kidneys don’t work—which damage the cells responsible for bone health.
Beyond bone fractures, kidney disease causes calcium to deposit abnormally in blood vessels and the heart, leading to cardiovascular disease. This vascular calcification is a major cause of death in kidney patients and represents a second major clinical syndrome alongside bone weakness.
The review identifies that protein-energy wasting (loss of muscle and body mass) is common in dialysis patients and worsens bone health. Additionally, the researchers found that current diagnostic tools have significant limitations. Standard bone density scans (DXA scans) can’t distinguish between different types of kidney-related bone disease and don’t work well when vascular calcification is present.
A newer imaging technique called trabecular bone score (TBS) shows promise for better predicting fracture risk, but large clinical trials are still needed to confirm its usefulness.
This review updates the traditional understanding of kidney-related bone disease. Historically, doctors focused mainly on secondary hyperparathyroidism (overactive parathyroid glands). The updated framework recognizes two distinct but overlapping syndromes: bone weakness with high fracture risk, and cardiovascular calcification. This represents a shift from viewing kidney bone disease as a single problem to understanding it as a complex condition affecting multiple body systems.
The review also highlights that despite decades of research, therapeutic nihilism persists—many doctors and patients believe nothing can be done, even though evidence-based treatments exist and are safe.
As a review article rather than a clinical trial, this work synthesizes existing knowledge but doesn’t provide new experimental data. The authors acknowledge that many diagnostic and predictive tools need improvement, and that large clinical trials with long-term follow-up are lacking for newer treatments. Some newer medications mentioned (like burosumab) have no published clinical trial data in kidney disease patients yet. The review also notes that bone biopsy, considered the gold-standard diagnostic test, is impractical for routine use. Finally, the authors emphasize that personalized risk stratification approaches are needed but not yet standardized in clinical practice.
The Bottom Line
Strong evidence supports screening for bone health in all patients with chronic kidney disease, particularly those on dialysis. Moderate evidence supports using bone-protective medications (bisphosphonates, denosumab, teriparatide) in high-risk patients, though more research is needed in kidney disease populations specifically. Doctors should abandon the assumption that nothing can be done and instead work with patients to develop personalized treatment plans based on individual risk factors. Patients should discuss bone health with their kidney doctor and ask about screening and treatment options.
Anyone with chronic kidney disease should prioritize bone health discussions with their nephrologist (kidney specialist). This is especially important for patients on dialysis, who face the highest fracture risk. Patients who have received a kidney transplant should also discuss bone health, as immunosuppressive medications increase fracture risk. Family members of kidney patients may also benefit from understanding this risk. However, the specific treatment recommendations should be individualized based on each patient’s kidney function, mineral levels, and other health conditions.
Bone health improvements typically take months to years to develop. Patients shouldn’t expect immediate fracture prevention, but consistent treatment over 12-24 months can improve bone quality. The timeline for seeing cardiovascular benefits from improved mineral control is even longer, potentially years. Fracture prevention is an ongoing process requiring sustained attention to mineral management, vitamin D levels, and medication adherence.
Frequently Asked Questions
Why do people with kidney disease have weaker bones?
Damaged kidneys can’t properly control phosphate and calcium minerals or activate vitamin D, which are essential for bone strength. Additionally, kidney disease causes harmful substances to accumulate that damage bone-building cells. These combined effects create bone weakness that looks different from regular osteoporosis.
How much higher is fracture risk in kidney disease patients?
Patients with chronic kidney disease have 4 times higher fracture risk than healthy people. Those on dialysis face up to 8 times higher risk. This means dialysis patients can break bones from minor falls that wouldn’t injure someone with healthy kidneys.
What treatments can help prevent fractures in kidney disease?
Several medications can help, including bisphosphonates, denosumab, teriparatide, and romosozumab. However, treatment must be personalized based on individual kidney function and mineral levels. Many high-risk patients aren’t receiving these treatments despite safety evidence, so discuss options with your nephrologist.
Can standard bone density scans detect kidney-related bone disease?
Standard DXA scans have limitations in kidney disease patients. They can’t identify the specific type of bone problem present and don’t work well when calcium deposits are in blood vessels. Newer imaging techniques like trabecular bone score show promise but need more research.
Does bone health improve after receiving a kidney transplant?
Kidney transplantation helps some aspects of bone health, but anti-rejection medications continue to weaken bones. Transplant patients still face elevated fracture risk and should discuss bone health monitoring and treatment with their doctor.
Want to Apply This Research?
- Track monthly phosphate and calcium lab values, vitamin D levels, and parathyroid hormone (PTH) results. Users should log these alongside any bone pain, falls, or injuries to identify patterns between mineral imbalances and bone health symptoms.
- Set reminders for bone-protective medication doses if prescribed. Log dietary phosphate intake (high in processed foods, dairy, nuts) and track adherence to kidney-friendly eating patterns. Record any falls or injuries, no matter how minor, to discuss with your doctor.
- Establish a quarterly review of lab trends with your nephrologist. Use the app to track whether mineral levels are improving with treatment. Monitor for new bone pain or increased fall risk as indicators that treatment adjustments may be needed. Share app data with your care team to support personalized risk stratification.
This article reviews scientific research on bone disease in kidney patients but is not medical advice. Bone health management in kidney disease requires personalized assessment by a qualified nephrologist or kidney specialist. Treatment decisions should be based on individual lab values, kidney function, and overall health status. If you have chronic kidney disease, discuss bone health screening and treatment options with your healthcare provider before starting any new medications or supplements. This review does not replace professional medical evaluation or treatment recommendations from your care team.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.